Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00279760 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 210
- Enrollment target
NCT00279760 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 210 participants.
The verdict
NCT00279760, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 210 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo controlled, parallel and multiple dose study provided safety, preliminary efficacy, and immunogenicity information about the use of BMS-188667 and BMS-224818 in subjects with RA
Interventions
- DRUG Abatacept
- DRUG Belatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00279760
The ClinicalTrials.gov registry entry for NCT00279760 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Abatacept is the first listed.
NCT00279760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00279760 about?
NCT00279760 is a clinical study titled "Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis". This randomized, double-blind, placebo controlled, parallel and multiple dose study provided safety, preliminary efficacy, and immunogenicity information about the use of BMS-188667 and BMS-224818 in subjects with RA
What is the current status of trial NCT00279760?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 210 participants.
What interventions are being tested in trial NCT00279760?
The interventions under investigation include: Abatacept (DRUG), Belatacept (DRUG).
Who is sponsoring clinical trial NCT00279760?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.